成大醫院血液科臨床試驗

Newly diagnosed Ph-negative B-cell precursor ALL. Adults aged >= 55 or aged 40–54 with specific comorbidities. ECOG performance status <= 2

Cohort A1: KMT2A-r AML Cohort A2: NPM1m AML

RRMM

Untreated & FLT3-ITD(-)

R/R

R/R CLL/SLL requiring treatment per iwCLL 2018 criteria with documented prior exposure to a covalent BTK inhibitor.

≥2 prior Tx (Including Lenalidomide and Proteasome Inhibitor )

≥1 prior Tx(Including Lenalidomide )

1. R/R 2. ≥2 prior Tx

newly diagnosed + stage, III or IV disease, or stage II with bulky disease

1. R/R 2. ≥2 prior Tx

1.≥2 prior Tx 2. CD19(+) 3. PH(+)->至少兩線TKI failure or replase 4. PH(-)->至少兩線systemic therapy failure

≥1 prior Tx

1. Newly diagnosed MM 2. ineligible for ASCT

4 cycle HMA/ LDAC or 2 cycle combination therapy failure for refractory group

≥1 prior Tx

≥1 prior Tx

after ASCT with NDMM

very low-, low-, intermediate risk MDS

JAK inhibitor naive

newly diagnosed + stage, III or IV disease, or stage II with bulky disease

Newly diagnosed

Untreated CLL/SLL

untreat

1. DLBCL(de novo or transformed indolent NHL, high-grade B with MYC+BCL2 ± BCL6 2. r/r within 12m from 1st treatment

1.R/R 2.≥1 prior Tx

Untreat or Eculizumab stop over 3 m or Ravulizumab stop over 6 m

Group 1: FLT3 ITD/TDK mutation Group 2: Spliceosome Mutation (SF3B1, SRSF2, U2AF1, ZRSR2)